Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab vs placebo in metastatic chemotherapy-naive castration-resistant prostate cancer
2009-016217-23Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Ipilimumab with Placebo (2 arms). Primary endpoint: Overall survival. Started Jun 2010; status: completed.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-016217-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016217-23.